The disorders of peroxisomal /?-oxidation, which have been well characterised at the molecular level, include defects of acyl-CoA oxidase, defects of the D-bifunctional protein (D-BP) (including specific defects of its enoyl-CoA hydratase and D-3-hydroxyacyl-CoA dehydrogenase components), defects of the very-long-chain fatty acid (VLCFA)-CoA importer [X-linked adrenoleukodystrophy (ALD)] and a-methylacyl-CoA racemase deficiency. A survey of the clinical consequences of these defects indicates that defects in the acyl-CoA oxidase and D-BP can produce neonatal hypotonia, seizures in early infancy, retinopathy and progressive neurological dysfunction with leukodystrophy on imaging. Defects in the VLCFA-CoA importer and in the racemase do not produce disease until a long time after the neonatal period. However, again the clinical picture is dominated by neurological disease : impaired cognitive function with leukodystrophy in childhood X-linked ALD and retinopathy and
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Introduction
The P-oxidation pathway in the peroxisomes is uniquely capable of catalysing the oxidation of straight-chain fatty acids with 24 or more carbon atoms [very-long-chain fatty acids, (VLCFA)] and the oxidation of compounds with a branched (isoprenoid) carbon chain [l] . This latter group of compounds includes pristanoyl-CoA (derived from the a-oxidation of phytanic acid in the diet) and C,, intermediates in bile acid synthesis, notably 3~,7a,l2~-trihydroxy-5~-cholestanoylCoA (THCA-CoA) and 3~,7a-dihydroxy-SPcholestanoyl-CoA (DHCA-CoA). Measurement of VLCFA, pristanic acid and C,, bile acids in plasma provides a very important means of diagnosing a peroxisomal disorder and goes some way towards defining the exact type ( Table 1) . Our current view of the peroxisomal P-oxidation pathway is shown in Scheme 1. VLCFA need to be activated by conversion into the CoA esters and transported into the peroxisomes ; the adrenoleukodystrophy (ALD) protein is thought to be involved in the transport process [2] . PristanoylCoA derived from a-oxidation of phytanic acid is a mixture of the (2R) and (223) by a-methylacyl-CoA racemase before p-oxidation [3] . Similarly, in the synthesis of bile acids from cholesterol, the first steps produce the (25R) isomer of THCA-CoA and the racemase is required to convert this into the (2.523) form before/?-oxidation.
The major pathway for @-oxidation of VLCFA-CoA and other straight-chain substrates is thought to proceed via a straight-chain acylCoA oxidase (palmitoyl-CoA oxidase), via the Dbifunctional protein (D-BP) (which has enoyl-CoA hydratase and D-3-hydroxyacyl-CoA dehydrogenase activities) and then via the 41 kDa 3-oxoacyl-CoA thiolase [l] . In contrast, (223)-pristanoyl-CoA and (25S)-THCA-CoA are oxidized by a branched-chain acyl-CoA oxidase, the D-BP and the sterol carrier protein, thiolase. This review will consider defects of palmitoyl-CoA oxidase, the D-BP, the 41 kDa thiolase, the A L D transporter protein and a-methylacylCoA racemase. T h e focus will be on patients whose defect has been established at the molecular level. Some comparisons will be made with children with defects of peroxisome biogenesis (e.g. cerebrohepatorenal syndrome of Zellweger, ZS) to illustrate the extent to which defective poxidation can produce the same clinical manifestations as a total absence or markedly decreased number of peroxisomes. Finally, reference will be made to unknown defects of peroxisomal poxidation. These are of two types: (1) patients with evidence of accumulation of VLCFA and/or pristanate and/or THCA/DHCA, in whom enzymology and molecular studies have not provided a definitive explanation, and ( 2 ) enzymes that are known to have a specific function but for which no case of defective activity has been described, e.g. branched-chain acyl-CoA oxidase deficiency and L-bifunctional protein deficiency.
Peroxisome biogenesis defects
Infants with the most severe form of biogenesis defect, ZS, are abnormal at birth with characteristic dysmorphic features, severe muscular hypotonia and intractable seizures [4] . T h e head is usually of normal size but the infant has a tall sloping forehead and shallow supra-orbital ridges, giving the skull and face a distinctive appearance. Vision is impaired with a reduced electroretinogram ; hearing is also affected with reduced brain stem auditory evoked reponses. Adrenal function is impaired, with a decreased cortisol response to stimulation with corticotropin. T h e infants show severely delayed development, fail to thrive and have evidence of liver dysfunction, with cirrhosis on a liver biopsy. They can have punctate stippling of the cartilages around the knee, hip and other joints (chondrodysplasia punctata). Survival is seldom beyond 1 year of age. At post mortem the brain shows evidence of defective neuronal migration during development and the kidneys have small glomerular cysts. Defects in peroxisome biogenesis can also lead to neonatal ALD in which dysmorphic features, hyopotonia and failure to thrive are not so severe but in which neurological deterioration occurs after a few months, concomitant with the appearance of white-matter changes on a computed tomography or magnetic resonance imaging (MRI) scan of the brain (leukodystrophy). In infantile Refsum disease, dysmorphic features are similar to Z S but more subtle; the hypotonia, delayed development, impaired vision and hearing and failure to thrive might not be apparent until 6 months to 1 year.
Palmitoyl-CoA oxidase deficiency
In 1998 Poll-The et al. described two siblings with 'pseudo-neonatal ALD' in whom immunoblotting showed an absence of the acyl-CoA oxidase [S] . This was later shown to be due to a deletion of more than 17 kb of the gene encoding palmitoyl-CoA oxidase, starting downstream of exon 2 and extending beyond the 3' end of the gene [6] . These two siblings were not dysmorphic but they had severe muscular hypotonia, albeit with preserved tendon reflexes. Seizures started shortly after birth and became almost constant and uncontrolled by anti-0 200 I Biochemical Society convulsants. T h e infants showed severely retarded psychomotor development. In the third year of life, the older sibling had evidence of hearing loss and also of loss of vision manifesting first with nystagmus, followed by loss of the pupillary light reflex with optic atrophy on fundoscopy and a reduced electroretinogram and absent cortical visual evoked response. Progressive neurological deterioration was evident from 2; years with hypertonia and hyper-reflexia in the limbs and additional dystonia in the arms. T h e clinical evidence of deterioration was associated with progression of abnormalities on the computed tomography scan of the brain, with development of extensive white-matter hypodensities and abnormal enhancement with contrast. Adrenal dysfunction was apparent from low plasma cortisol and raised plasma corticotropin concentrations. Plasma concentrations of VLCFA were elevated but the concentrations of phytanate and C,, bile acids were normal. Intact fibroblasts showed decreased oxidation of lignonerate (CZ6, o) and the liver peroxisomes were of variable size and shape. T h e second sibling showed very similar clinical abnormalities but additionally showed mild hepatomegaly in the neonatal period and tapetoretinal degeneration on fundoscopy at age 2 years.
Wanders et al. [7] described a further case of palmitoyl-CoA oxidase deficiency, diagnosed by immunoblot analysis. Suzuki et al. [S] added two further cases and Watkins et al. [9] a further five cases, all diagnosed by lack of complementation with the fibroblasts from the patients of Poll-The et al. These ten cases confirmed that dysmorphic features are unusual, although the two siblings described by Suzuki et al. had hypertelorism, epicanthic folds, a low nasal bridge, low-set ears and polydactyly. All patients had marked hypotonia (but sometimes with preserved reflexes) and seizures (but onset of seizures was often between 2 and 4 months and could sometimes be controlled with medication). All showed psychomotor delay but almost all acquired some gross and fine motor skills. Most subsequently showed regression and/or the appearance of a leukodystrophy on imaging. Adrenal insufficiency was common but liver involvement was mild, with slight hepatomegaly and hepatic fibrosis being described.
T h e average age of death was approx. 4 years.
D-BP deficiency
T h e first description of a patient with bifunctional protein deficiency was from Watkins et al. [lo] . In contrast with patients with palmitoyl-CoA oxidase deficiency, patients with D-BP deficiency have shown little or no developmental progress. However, in both disorders, definite regression has been described. T h e patients with a total absence of D-BP died between the ages of 6 months and 2 years.
Further cases of D-BP deficiency have been identified by the failure of their fibroblasts to complement fibroblasts from the patient of Watkins et al. [lo] . Some of these patients could have a defect in only one component of the D-BP (see below) but the clinical features of the patients were broadly similar to those described for total D-BP deficiency [9] . Dysmorphic features were present in 14 of 15, with macrocephaly in 10 of 12, a prominent forehead, flat nasal bridge and micrognathia. All had profound neonanatal hypotonia, 14 of 15 had neonatal seizures and 13 of 15 had seizures after the neonatal period. All showed no developmental progress, scans showed leukodystrophy in 6 of 8
and there was evidence of a neuronal migration defect in 7 of 8. Liver abnormalities were mild; several had osteoporosis. Mean age at death was 9 months.
Deficiency of the hydroxyacyl-CoA dehydrogenase component of the D-BP
Among patients identified by a lack of complementation with the D-BP-deficient patient of Watkins et al. [lo] , there were patients who did complement one another : ' intragenic complementation'. In one group, the main bile acid in plasma was varanic acid [(24<,25<)-3a,7a,l2a,24- tetrahydroxy-5P-cholestanoic acid] ; this suggested that the defect was likely to be in the hydroxyacyl-CoA dehydrogenase component of the bifunctional protein. T h e first patient shown to have a defect of this type by both molecular and enzymic studies was described by van Grunsven et al. [13] . The patient was homozygous for a substitution of serine for glycine at residue 16. This is predicted to affect the NAD+-binding site. This patient was abnormal at birth, with a high forehead and frontal bossing, a large fontanelle and low-set ears. He also had hypospadias. He was hypotonic with muscle wasting and had seizures. Mild hepatomegaly was documented. An MRI scan showed dysmyelination.
Deficiency of the enoyl-CoA hydratase component of the D-BP
One subgroup of patients with D-BP deficiency complemented the patients with hydroxyacylCoA dehydrogenase deficiency and had no varanic acid (or other bile acid intermediates) in plasma. T h e complementation studies suggested the possibility of deficiency of the enoyl-CoA hydratase component of the D-BP. This was confirmed enzymically by Grunsven et al. [14] and they went on to show that two patients in the group were homozygous for an A~n~~~+ T y r mutation in the enoyl-CoA hydratase coding region of the D-BP gene. These first patients with proven enoyl-CoA hydratase deficiency were abnormal from birth with hypotonia, refractory seizures, severe psychomotor delay and possibly impaired vision and/or hearing (they failed to respond to auditory or visual stimuli and to fix and follow with their eyes). Dysmorphic features were subtle in one infant (shallow supra-orbital ridges only) but the other had macrocephaly and a typical Zellweger facies. Both developed hydrocephalus, one at 3 months and one at 8 months. One died at 4 months and the other at 1 year.
Deficiency in 4 I kDa thiolase
Only one patient with deficiency of the 41 kDa thiolase has been described so far; this patient was diagnosed on the basis of immunoblotting of the peroxisomal B-oxidation proteins in the liver (absence of thiolase) [15, 16] . A molecular defect has not been confirmed. T h e infant was abnormal from birth with profound hypotonia (and absent tendon reflexes), intractable seizures and subtle dysmorphic features (high arch palate, flattened chest with flared ribs). She made no developmental progress and had reduced visual evoked responses from the occipital cortex. She had a ventricular septa1 defect and developed cardiac failure. She died at 11 months. Mild hepatic fibrosis was present at post-mortem.
X-linked ALD (X-ALD)
Much has been written on the clinical manifestations of X-ALD, which is the consequence of mutations in the A L D protein, an ATP-binding cassette protein that is probably necessary for import of VLCFA-CoA into the peroxisomes [17] . This review will contain a brief summary, focusing on the commonest type, childhood ALD. In contrast with the patients described so far, boys with A L D are entirely normal at birth. They have no dysmorphic features, a normal muscle tone, no seizures and a normal early psychomotor development. Onset of symptoms is usually at approx. 7.2 years (range 2.75-10 years) with changes in behaviour (emotional lability, withdrawal or hyperactive behaviour). At the same time there can be perceptive or intellectual difficulties (specifically difficulty understanding speech, attention deficit, astereognosis and graphaesthesia). These problems often progress to expressive and motor difficulties (apraxia, dysarthria and dysphasia followed by a spastic gait or hemiparesis with hyperreflexia). Visual disturbance is common with, initially, reduced visual fields and acuity, but later strabsimus and optic atrophy. Focal or generalized seizures occur as a late feature of the disease. Symptoms and signs of adrenal insufficiency include weakness and tiredness, anorexia, vomiting and diarrhoea/constipation, pigmentation (including involvement of the mucous membranes) and crises with abdominal pain, vomiting and dehydration. MRI images of the brain in boys with A L D characteristically show abnormalities of the occipital white matter with a surrounding area that enhances with contrast.
Other 
a-Methylacyl-CoA racemase deficiency
T h e first cases of a-methylacyl-CoA racemase deficiency were described by Ferdinandusse et al. [3] . One case was a SO-year-old woman who complained that her legs felt heavy on exercise and that she was dragging her feet on walking. She had difficulty getting out of a chair and walking upstairs. Examination revealed a spastic paraparesis; nerve conduction studies showed that she also had a demyelinating polyneuropathy. An M R I scan showed non-specific changes (prominent areas of signal in the thalami in T, weighted scans with low signal in mode). Plasma VLCFA levels were normal, phytanic acid concentrations varied from normal to mildly elevated, and pristanic acid, DHCA and T H C A levels were markedly elevated. Dietary restriction of phytanic acid led to a decrease in pristanate levels ; after this treatment she was stronger and was, for example, able to walk up stairs. A second patient with racemase deficiency, a man in his thirties, had had mild learning difficulties during childhood. He had developed an encephalitic illness at 18 years that had led to a loss of vision, which was followed by partial recovery then loss of acuity again with restriction of visual fields and evidence of pigmentary retinopathy on fundoscopy. Further neurological assessment showed signs of a sensory motor neuropathy affecting the arms more than then legs; nerve conduction studies suggested an axonal neuropathy. T h e patient also suffered from epilepsy and primary hypogonadism. A further case of racemase deficiency has been diagnosed in an adult female with sensory motor neuropathy and pigmentary retinopathy and increased plasma concentrations of phytanate and pristanate. Our conclusion at present must be that the major clinical manifestations of racemase deficiency must be adult-onset sensory motor neuropathy and pigmentary retinopathy.
Conclusions
A comparison of the clinical consequences of specific defects of peroxisomal /%oxidation is shown in Table 2 . It is clear that defects in palmitoyl-CoA oxidase and in the D-BP can cause oxidation can produce an accumulation of substrates that is greater than that seen in X-ALD, it is difficult to escape the conclusion that defective peroxisomal /?-oxidation has effects (such as neuronal migration defects) that are more serious than those produced by the accumulation of substrates alone.
Unknown defects of peroxisomal /I-oxidation
A variety of patients have been described who have evidence of defective peroxisomal p-oxidation but whose precise defect has not been determined. One clinical syndrome is the onset of ataxia in a 4-5-year-old child with elevated pristanate and C,, bile acid levels but normal VLCFA concentrations. Fibroblasts show normal oxidation of branched-chain substrates and racemase activity is normal [18, 19] . In another scenario, we are currently studying two Turkish families with two affected children in each family. T h e clinical picture is one of progressive spastic paraparesis during the preschool and school years with ataxia and neuropathy but preserved cognitive functioning. MRI scans show dysmyelination ; plasma concentrations of VLCFA and pristanate (but not C,, bile acids) are elevated. It is clear that continuing studies of patients with peroxisomal disorders will contribute to our understanding of the biochemistry of the peroxisome.
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